Episode 121
š§¬ Dr. Kate Yen: Scaling a Biotech, Running Lean, & Utilizing Translational Biology (Part 2)
āI didnāt set out to be an entrepreneur, but when I couldnāt find a company doing what I believed in, I built my own.ā In part two of our conversation with Kate Yen, Founder and CEO of Auron Therapeutics, we explore her journey from leading a novel cancer therapy program at Agios to founding her own biotech company. Kate shares insights into drug development, clinical trials, and the business of biotech, highlighting the importance of translational biology, strategic partnerships, and lean operations in building a successful biotech startup. Kate earned her Ph.D. in Biological Chemistry from UCLA, where she also completed her postdoc. Before Auron, she held roles at Merck and as a UCLA professor before joining Agios Pharmaceuticals, where she led the IDH translational research team behind two FDA-approved IDH mutant inhibitors and co-led the discovery of vorasidenib, a promising glioma therapy now in clinical development.
The Biotech Startups Podcast Ā· Excedr
February 20, 202551m 36s
Audio is streamed directly from the publisher (media.fame.so) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
š§¬ The Biotech Startups Podcast is powered by Excedrāhelping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.
As a TBSP listener, you get exclusive perks through Excedrās partner networkāspecial savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners.
āI didnāt set out to be an entrepreneur, but when I couldnāt find a company doing what I believed in, I built my own.ā
In part two of our conversation with Kate Yen, Founder and CEO of Auron Therapeutics, we explore her journey from leading a novel cancer therapy program at Agios to founding her own biotech company.
Kate shares insights into drug development, clinical trials, and the business of biotech, highlighting the importance of translational biology, strategic partnerships, and lean operations in building a successful biotech startup.
Kate earned her Ph.D. in Biological Chemistry from UCLA, where she also completed her postdoc. Before Auron, she held roles at Merck and as a UCLA professor before joining Agios Pharmaceuticals, where she led the IDH translational research team behind two FDA-approved IDH mutant inhibitors and co-led the discovery of vorasidenib, a promising glioma therapy now in clinical development.
Key topics covered:
- Navigating clinical trials from discovery to FDA approval with a biomarker-driven approach
- The importance of translational biology and how Auron integrates it from day one
- Building a lean biotech startup, from early fundraising to assembling a high-impact team
- Securing big pharma partnerships in a challenging biotech market
- Leveraging AI and machine learning to map cancer biology and identify new drug targets
If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening.
Subscribe to the podcast:
Youtube: https://www.youtube.com/@excedr
Find our guest, Kate Yen, at these links:
Website: https://www.aurontx.com/
Find our host, Jon Chee, at these links:
LinkedIn: https://www.linkedin.com/in/jonchee
Learn more about Excedr
LinkedIn: https://www.linkedin.com/company/excedr/
Website: https://www.excedr.com
Resources & articles mentioned:
The Role of Translational Biology in Drug Development: https://www.sciencedirect.com/science/article/abs/pii/S1359644612004060
Navigating Clinical Trials: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process
Building & Running a Lean Biotech Startup: https://www.lablaunch.org/post/building-a-lean-biotech-startup
Biotech Startup Fundraising Options: https://www.excedr.com/resources/biotech-startup-funding-options
Biotech Partnerships - How Partnerships Support R&D: https://www.excedr.com/blog/how-biotech-partnerships-support-research
How to Bootstrap Your Biotech Startup & Scale: https://www.excedr.com/resources/how-to-bootstrap-biotech-startup
How to Choose the Right CRO for Biotech: https://www.excedr.com/blog/contract-research-organizations
How Much Does Lab Space Cost? https://www.excedr.com/blog/how-much-does-lab-space-cost
Top VC Firms for Biotech in 2024 - Supporting Innovation & Growth: https://www.excedr.com/blog/top-vc-firms-for-biotech
50 Biotech Seed & Angel Investors to Check Out in 2025: https://www.excedr.com/blog/biotech-seed-and-angel-investors
Companies & people mentioned:
Auron Therapeutics: https://www.aurontx.com/
Merck: https://www.merck.com/
Agios Pharmaceuticals: https://www.agios.com/
UCLA: https://www.ucla.edu/
Princeton University: https://www.princeton.edu/
Charles Sawyers: https://en.wikipedia.org/wiki/Charles_Sawyers
Lew Cantley: https://en.wikipedia.org/wiki/Lewis_C._Cantley
David Schenkein: https://www.linkedin.com/in/david-schenkein-md-45342476/
Timestamps:
00:00 Intro
02:10 Kate Yenās transition into leadership at Agios
05:39 Navigating clinical trials and biomarker-driven decision-making
10:29 The importance of translational biology in drug development
14:19 Taking the leap to start Auron Therapeutics
18:36 Raising early funding and building a lean biotech startup
26:41 Leveraging AI and machine learning in cancer drug discovery
30:58 Running a biotech startup with a sustainable and transparent culture
41:07 Fundraising strategies to expanding Auronās platform beyond oncology
47:08 Closing questions for Kate
49:35 Outro
The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science companyāfrom pre-seed to IPO.